At a glance
- Originator Novartis
- Class Indenes; Nonsteroidal anti-inflammatories; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatic disorders
Most Recent Events
- 16 Feb 1995 Discontinued-III for Rheumatic disorders (Unknown route)